Biogen+Idec

= Biogen Idec = ==

General Information
toc Susan H. Alexander - executive vice president, general counsel and corporate secretary Paul J. Clancy - executive vice president and chief financial officer Robert A. Hamm - chief operating officer Michael Lytton - executive vice president, corporate and business development Michael F. MacLean - senior vice president, chief accounting officer and controller Craig Eric Schneier, Ph.D. - executive vice president, human resources, public affairs & corporate communications ||
 * ~ Company Name || Biogen Idec ||
 * ~ Year founded || 2003 ||
 * ~ Headquarters || Cambridge, Massachusetts U.S. ||
 * ~ **Global Locations** || Switzerland, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, India, Ireland, Italy, Japan, New Zealand, Norway, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, United Kingdom ||
 * ~ Management || James C. Mullen - president and chief executive officer
 * ~ Revenue || 3.17 billion USD ||
 * ~ Employees || 4,300 ||
 * ~ Products || Avonex, Rituxan, Tysabri ||
 * ~ website || www.biogenidec.com ||

Biogen Idec, Inc. is a biotechnology company working on drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the fusion of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals.

History
Biogen gathered a team of biologists, each making breakthrough science in small labs. The emphasis was on significant science. The two co-founders, Phillip Sharp and Walter Gilbert won the Nobel Prize. Biogen was one of the first companies to develop recombinant proteins using genetic technology, what led to the development of AVONEX®, an interferon beta-1a used to treat multiple sclerosis. After several years, in 1985, IDEC was founded by a group of California-based research scientists searching for a method to use monoclonal antibodies for treating cancer. California and Silicon Valley were bursting with venture capitalists, and a group of them teamed up with the scientists to form IDEC. A RITUXAN® is the solving for their initial researching. After fusion in 2003, companies were transformed into the third-largest biotechnology company in the world. The merger allowed Biogen Idec to scale up the research and development, manufacturing, FDA approval mechanisms and infrastructure required to launch important new therapies. Biogen Idec is an attractive partner for smaller labs and biotechnology companies developing new treatments (partnerships like this now account for an important percentage of all new drugs approved by the FDA). Biogen Idec stock is a component of several stock indices such as the S&P 500. S&P 1500 and NASDAQ-100.

AVONEX® (Interferon beta-1a) has the most treatment experience for relapsing forms of MS worldwide, with more than 135,000 patients on therapy. It is used on a global scale as a treatment for relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is also for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS. The most common side effects are flu-like symptoms, including myalgia, fever, fatigue, headache, chills, nausea, vomiting, pain and asthenia.

RITUXAN® (rituximab) is approved for treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens; for previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy; and for the treatment of non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent, after first-line CVP chemotherapy. RITUXAN is also approved for use in connection with methotrexate (MTX) for reducing signs and symptoms and to slow the progression of structural damage in adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

TYSABRI® (natalizumab) is a medicine approved for relapsing forms of multiple sclerosis in the United States and relapsing-remitting MS in the European Union. After two years, TYSABRI treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001) - according to data that have been published in the New England Journal of Medicine TYSABRI was recently accepted in the U.S. for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha. Common adverse effects reported in TYSABRI-treated MS patients are: headache, fatigue, infusion reactions, urinary tract infections, joint and limb pain, and rash. Other common adverse events reported in TYSABRI-treated CD patients include respiratory tract infections and nausea. Clinically significant liver injury has been reported in patients treated with TYSABRI in the post-marketing setting. source: www.biogenidec.com

Products in the pipeline

 * PROLONGED RELEASE FAMPRIDINE || Multiple Sclerosis ||
 * PEG IFN (PEGYLATED INTERFERON BETA-1A) || Multiple Sclerosis-Relapsing Forms ||
 * BG-12 (DIMETHYL FUMARATE) || Multiple Sclerosis-Relapsing Forms ||
 * DACLIZUMAB || Multiple Sclerosis-Relapsing Forms ||
 * HUMANIZED ANTI-CD20 MAB (OCRELIZUMAB) || Multiple Sclerosis-Relapsing Forms ||
 * BIIB014/V2006 || Parkinson's Disease ||
 * NEUBLASTIN || Neuropathic Pain ||
 * Anti-LINGO || Multiple Sclerosis ||
 * HUMANIZED ANTI-CD20 MAB (GA101) || Chronic Lymphocytic Leukemia ||
 * HUMANIZED ANTI-CD20 MAB (GA101) || Non-Hodgkin's B-Cell Lymphoma ||
 * ANTI-CD23 MAB (LUMILIXIMAB) || Chronic Lymphocytic Leukemia ||
 * ANTI-CD80 MAB (GALIXIMAB) || Non-Hodgkin's Lymphoma ||
 * HSP90 INHIBITOR || Solid Tumors ||
 * ANTI-IGF-1R || Solid Tumors ||
 * M200 (VOLOCIXIMAB) || Solid Tumors ||
 * ANTI-CRIPTO MAB || Solid Tumors ||
 * FUMADERM (FUMARIC ACID ESTERS) || Psoriasis (Germany) ||
 * HUMANIZED ANTI-CD20 MAB (OCRELIZUMAB) || Rheumatoid Arthritis ||
 * BG-12 (DIMETHYL FUMARATE) || Rheumatoid Arthritis ||
 * ANTI-TWEAK || Rheumatoid Arthritis ||
 * LONG ACTING rFACTOR IX || Hemophilia B ||
 * LONG ACTING rFACTOR VIII || Hemophilia A ||
 * LIXIVAPTAN || Acute heart failure with hyponatremia ||
 * LIXIVAPTAN || Congestive heart failure ||